Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

Mini Oral session - Immunotherapy of cancer

Association of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials

Date

24 Nov 2019

Session

Mini Oral session - Immunotherapy of cancer

Presenters

Yunfang Yu

Citation

Annals of Oncology (2019) 30 (suppl_9): ix107-ix114. 10.1093/annonc/mdz438

Authors

Y. Yu, A. Li, Y. Chen, Q. Li, Q. Ou, D. Lin, W. Zhang, Z. Li, H. Hu, H. Yao

Author affiliations

  • Guangdong Provincial Key Laboratory Of Malignant Tumor Epigenetics And Gene Regulation, Department Of Oncology And Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.